Mereo BioPharma Group PLC
MREO1.760USD
0.000
交易中 （美东）报价延迟15分钟
1.40B总市值
亏损市盈率 TTM
关于 Mereo BioPharma Group PLC 公司
Mereo BioPharma Group plc 是一家专注于开发罕见病治疗药物的生物制药公司。该公司已开发了一系列后期临床候选产品，其两种罕见病候选产品是用于治疗成骨不全症 (OI) 的 setrusumab 和主要用于治疗严重 α-1 抗胰蛋白酶缺乏症相关肺病 (AATD-LD) 的 alvelestat。除了罕见病项目外，该公司还有两种肿瘤候选产品处于临床开发阶段。Etigilimab 是一种 IgG1 单克隆抗体，可与免疫细胞上具有 Ig 和 ITIM 结构域 (TIGIT) 受体的人类 T 细胞免疫受体结合，以提高 T 细胞和 NK 细胞抗肿瘤活性的激活和有效性。Navicixizumab 是一种双特异性抗体，可抑制 delta 样配体 4 (DLL4) 和血管内皮生长因子 (VEGF)。Navicixizumab 被开发用于治疗晚期卵巢癌。
公司简介
公司代码MREO
公司名称Mereo BioPharma Group PLC
上市日期Jun 09, 2016
CEODr. Denise V. Scots-Knight, Ph.D.
员工数量36
证券类型Depository Receipt
年结日Jun 09
公司地址One Cavendish Place
城市LONDON
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编W1G0QF
电话443330237300
网址https://www.mereobiopharma.com/
公司代码MREO
上市日期Jun 09, 2016
CEODr. Denise V. Scots-Knight, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Charles E. Sermon
Mr. Charles E. Sermon
General Counsel and Business Development, Company Secretary
General Counsel and Business Development, Company Secretary
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine Fox
Ms. Christine Fox
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+174.32%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+61.20%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Roberts
Mr. Justin Roberts
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
11.12%
Rubric Capital Management LP
9.62%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Mangrove Partners
5.43%
其他
61.04%
持股股东
持股股东
占比
Janus Henderson Investors
11.12%
Rubric Capital Management LP
9.62%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Mangrove Partners
5.43%
其他
61.04%
股东类型
持股股东
占比
Hedge Fund
31.41%
Investment Advisor/Hedge Fund
17.13%
Venture Capital
6.90%
Private Equity
5.93%
Investment Advisor
4.42%
Research Firm
3.16%
Individual Investor
0.86%
Bank and Trust
0.12%
其他
30.07%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
167
124.56M
78.34%
-3.58M
2025Q1
176
112.84M
70.99%
-23.15M
2024Q4
174
116.69M
75.21%
-16.90M
2024Q3
167
107.29M
69.42%
-17.56M
2024Q2
164
101.82M
66.22%
-5.20M
2024Q1
162
84.96M
60.56%
-41.79M
2023Q4
143
78.69M
56.11%
-37.03M
2023Q3
141
72.18M
51.57%
-33.53M
2023Q2
149
64.87M
50.46%
-34.19M
2023Q1
152
61.46M
49.21%
-39.78M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
22.74M
14.3%
+5.61M
+32.78%
Mar 31, 2025
Rubric Capital Management LP
15.31M
9.63%
--
--
Mar 31, 2025
Northpond Ventures, LLC
10.90M
6.86%
+10.90M
--
Jun 04, 2025
Frazier Life Sciences Management, L.P.
8.07M
5.08%
+250.00K
+3.20%
Apr 01, 2025
Mangrove Partners
8.64M
5.43%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
6.71M
4.22%
--
--
Mar 31, 2025
Alkeon Capital Management LLC
4.70M
2.95%
--
--
Mar 31, 2025
Rock Springs Capital Management LP
6.68M
4.2%
-2.91M
-30.37%
Mar 31, 2025
683 Capital Management LLC
4.63M
2.92%
+85.00K
+1.87%
Mar 31, 2025
Clearline Capital LP
3.22M
2.02%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
0.9%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
SPDR S&P International Small Cap ETF
0.02%
ActivePassive International Equity ETF
0%
Formidable ETF
0%
Tema Heart & Health ETF
0%
Tema Oncology ETF
0%
iShares Genomics Immunology and Healthcare ETF
占比0.9%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.88%
SPDR S&P International Small Cap ETF
占比0.02%
ActivePassive International Equity ETF
占比0%
Formidable ETF
占比0%
Tema Heart & Health ETF
占比0%
Tema Oncology ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
